NASDAQ:OLMA Olema Pharmaceuticals Q2 2026 Earnings Report $9.82 -0.08 (-0.81%) Closing price 04:00 PM EasternExtended Trading$9.85 +0.03 (+0.27%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Olema Pharmaceuticals EPS ResultsActual EPS-$0.61Consensus EPS -$0.55Beat/MissMissed by -$0.06One Year Ago EPSN/AOlema Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOlema Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time4:00PM ETUpcoming EarningsOlema Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Olema Pharmaceuticals Earnings HeadlinesStifel Nicolaus Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)September 17 at 9:05 PM | theglobeandmail.comOlema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15 at 5:00 PM | seekingalpha.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 18 at 1:00 AM | Traders Agency (Ad)Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial ResultsSeptember 14, 2026 | finance.yahoo.comCiti Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)September 12, 2026 | theglobeandmail.comOlema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comSee More Olema Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email. Email Address About Olema PharmaceuticalsOlema Pharmaceuticals (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women with cancer, particularly hormone receptor-positive breast cancer. The company’s research is centered on treatments designed to address the biological drivers of tumor growth and provide new options for patients with advanced or metastatic disease. Olema’s lead investigational product is palazestrant, an oral selective estrogen receptor degrader (SERD) being evaluated for the treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The company is studying palazestrant as a potential treatment both as a single agent and in combination with other targeted cancer therapies. Because the product remains investigational, it has not been established as safe or effective for commercial use. Olema was founded in 2013 and is headquartered in San Francisco, California. The company conducts research and clinical development activities through collaborations and clinical trial sites in the United States and other international locations. Olema is led by President and Chief Executive Officer Sean Bohen, M.D., Ph.D., who has experience in oncology drug development.View Olema Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
